Jump to content

Drilldown: Medicines

Pharmacopedia
BrowseCategoriesLog in

Choose a table:


Medicines > fda max: 6 mg/d (psychosis/mania); 3 mg/d (depression adjunct) & routes : Oral or Subcutaneous (abdomen

Use the filters below to narrow your results.

generic:
None (1)
brand:
Vraylar (1)
classes:
Atypical antipsychotic (1) · D2/D3/5HT1A partial agonist (1)
mechanism:
None (1)
uses:
Schizophrenia (FDA-approved 2015). Acute manic or mixed episodes of bipolar I disorder. Bipolar I depression (FDA-approved 2019). Adjunctive treatment of major depressive disorder (FDA-approved Dec 2022). (1)
starting dose:
Schizophrenia: 1.5 mg PO daily, increase to 1.5-6 mg as tolerated. Bipolar mania: 1.5 mg, may increase to 3-6 mg. Bipolar depression: 1.5 mg daily for 14 days, then 3 mg. MDD adjunct: 1.5 mg, may increase to 3 mg. (1)
preparations:
1.5 mg, 3 mg, 4.5 mg, 6 mg capsules (1)
fda max: (Click arrow to add another value)
routes: (Click arrow to add another value)
onset:
Weeks for psychosis/mood efficacy (1)
duration:
Daily dosing; active metabolites with very long half-lives (up to 1-3 weeks) (1)
halflife:
Cariprazine ~2-4 d; major active metabolites desmethyl-cariprazine (DCAR) ~1-3 weeks → 'oral depot' effect with delayed steady-state and reduced effect of missed doses (1)
bioavailability:
Adequate oral bioavailability (1)
pregnancy:
Limited data (1)
legal:
Rx (1)

Showing below up to 1 result in range #1 to #1.

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)


View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"